Optimizing Immunotherapy in Resectable NSCLC: Adjuvant, Neoadjuvant, and Perioperative Strategies
February 26th 2025The administration of immunotherapy in adjuvant, neoadjuvant, and perioperative settings offers distinct benefits and challenges in resectable cancers, with recent clinical trials highlighting its potential to improve long-term outcomes and the need for further research into biomarkers and combination strategies.
Read More
Lifileucel Approval Paves the Way for Personalized Minimally-Invasive T-Cell Therapies
February 25th 2025The FDA’s accelerated approval of lifileucel (Amtagvi; Iovance Biotherapeutics) marks a major milestone in immunotherapy for metastatic melanoma, building on decades of research in tumor-infiltrating lymphocyte therapy.
Read More
James P. Allison and the Discovery of CTLA-4: How Immune Checkpoint Blockade Revolutionized Oncology
February 25th 2025Immunotherapy pioneer James P. Allison, PhD, revolutionized cancer treatment by discovering immune checkpoint blockade, leading to significant advances in survival rates and ongoing efforts to optimize immuno-oncology strategies.
Read More
Emerging Role of BRAF Inhibitors in Relapsed/Refractory Hairy Cell Leukemia Treatment
BRAF V600E inhibitors show improved outcomes in relapsed/refractory hairy cell leukemia.
Read More
Key Considerations for Pharmacists in Hemophilia B Treatment With Etranacogene Dezaparvovec
February 24th 2025Etranacogene dezaparvovec offers a long-term, cost-effective solution for hemophilia B by providing sustained factor IX expression but requires careful patient selection and post-infusion liver monitoring.
Watch